List of Zurampic drug patents
Zurampic is owned by Ironwood Pharms Inc.
Zurampic contains Lesinurad.
Zurampic has a total of 9 drug patents out of which 0 drug patents have expired.
Zurampic was authorised for market use on 22 December, 2015.
Zurampic is available in tablet;oral dosage forms.
Zurampic can be used as reduction of serum uric acid levels; treatment of hyperuricemia; treatment of gout, achieving a therapeutic benefit in a subject with gout; treatment of gout, treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone, coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; below 6mg/dl in patients having uric acid deposits; and/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%, reduction of serum uric acid levels, treatment of hyperuricemia.
The generics of Zurampic are possible to be released after 29 February, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(2 years from now) | |
| US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(6 years from now) | |
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(6 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(6 years from now) | |
| US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(8 years from now) | |
| US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(8 years from now) | |
Drugs and Companies using LESINURAD ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Achieving a therapeutic benefit in a subject with gout; Treatment of gout; Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of hyperuricemia; Reduction of serum uric acid levels; Coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; Below 6mg/dl in patients having uric acid deposits; And/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%
Dosage: TABLET;ORAL
ZURAMPIC family patents
62
United States
13
European Union
11
Japan
9
China
7
Korea, Republic of
7
Australia
7
South Africa
7
EA
7
New Zealand
6
Brazil
6
Canada
5
Spain
5
Israel
5
Mexico
4
Hong Kong
4
RS
4
Poland
4
Lithuania
4
Ukraine
4
Cyprus
4
Slovenia
4
Hungary
4
Portugal
4
Singapore
4
Croatia
4
Taiwan, Province of China
4
Denmark
3
Argentina
3
ME
2
Austria
2
Chile
2
Malaysia
2
Luxembourg
2
Norway
2
Ecuador
1
Morocco
1
Netherlands
1
Tunisia
1
Colombia
1
Turkey
1
India
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic